

Date: August 14, 2019

To
The Department of Corporate Services
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001

Scrip Code: BSE: 526301

Dear Sir,

Sub: Un-Audited Financial Results for the Quarter ended 30th June, 2019
(Standalone and Consolidated)


In compliance with Regulation 33 & 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find the enclosed Un-Audited Financial Results for the first quarter ended 30th June, 2019 (Standalone and Consolidated) which have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 14th August, 2019 and also the Limited Review Report furnished by the Statutory Auditors of the Company.

The meeting of the Board of Directors of the Company commenced at 11.30 A.M and concluded at 3.30 P.M.

This is for your information and record.

Thanking you,

Yours faithfully
For Medinova Diagnostic Services Limited


Sunil Chandra Kondapally
Managing Director



MEDINOVA DIAGNOSTIC SERVICES LIMITED

CIN: L85110TG1993PLC015481

Regd. Office : 7-1-58/A/ FF8 , Flat No. 8, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2019

(Rs. in Lakhs)

Sl. No.	Particulars	Quarter Ended			Year Ended
		30.06.2019 (Unaudited)	31.03.2019 (Unaudited)	30.06.2018 (Unaudited)	31.03.2019 (Audited)
1	Income:				
	(a) Revenue from operations	145.83	168.86	168.48	674.33
	(b) Other Income	3.14	9.74	3.47	16.96
	Total Income	148.97	178.60	171.95	691.29
2	Expenses				
	(a) Cost of Material Consumed	23.99	23.62	31.57	112.11
	(b) Employees benefit Expense	43.03	30.47	52.95	206.55
	(c) Finance Costs	11.42	11.25	4.49	43.21
	(d) Depreciation & Amortisation Expenses	10.24	13.98	13.35	55.15
	(e) Other Expenses	72.58	74.95	85.46	325.21
	Total Expenses	161.26	174.27	187.82	742.23
3	Profit / (Loss) before Exceptional and Extraordinary items and Tax (1-2)	(12.29)	4.33	(15.87)	(50.94)
4	Exceptional Items	-	161.32	-	161.32
5	Profit/(Loss) before Extraordinary items and Tax (3+4)	(12.29)	165.65	(15.87)	110.38
6	Extraordinary Items	-	-	-	-
7	Profit / (Loss) before Tax (5-6)	(12.29)	165.65	(15.87)	110.38
8	Tax Expenses				
	(a) Current Tax	-	-	-	-
	(b) Deferred Tax (Credit) /Charge	-	1.08	-	1.08
	(c) Taxes of earlier years	-	32.50	-	32.50
9	Profit / (Loss) for the period (7-8)	(12.29)	132.07	(15.87)	76.80
10	Other Comprehensive income	-	(1.57)	0.00	(1.57)
11	Total Comprehensive income for the period (9+10)	(12.29)	130.50	(15.87)	75.23
12	Paid-up Equity Share capital (Face Value Rs 10/- per share)	995.68	995.68	995.68	995.68
13	Earnings per Equity Share				
	a) Basic (Rs.)	(0.12)	1.30	(0.16)	0.75
	b) Diluted (Rs.)	(0.12)	1.30	(0.16)	0.75

Notes to Standalone Financial Results for the Quarter Ended 30th June, 2019

- The financial results of the company have been prepared in accordance with the Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act., 2013, read with the relevant rules issued thereunder.
- The above financial results were reviewed by the Audit Committee and have been considered and approved by the Board of Directors at its meeting held on 14th August, 2019. The statutory Auditors of the company have carried out limited review of these results and the results are being published in accordance with regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.
- As the company's business activity falls within a single primary business segment (viz Diagnostic Services) the disclosure requirements of Accounting Standard (AS-108) "Operating Segments" issued by the Institute of Chartered Accountants of India are not applicable.
- Figures for the previous periods have been regrouped /rearranged wherever necessary to conform with the current period.

for MEDINOVA DIAGNOSTIC SERVICES LTD.

SUNIL CHANDRA KONDAPALLY
MANAGING DIRECTOR
DIN 01409332

Place : Hyderabad

Date : 14.08.2019





Limited Review Report on Unaudited Standalone Financial Results

To
The Board of Directors
Medinova Diagnostic Services Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Medinova Diagnostic Services Limited ("the company") for the Quarter ended 30th June 2019, ("the Statement") being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Regulations), as amended read with SEBI Circular: No. CIR/CFD/CMD1/44/2019 dated 29th March 2019 ('the Circular').
2. The preparation of the Statements in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India read with circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company in their meeting held on 14th August 2019. Our responsibility is to issue a report on the Statement based on our review
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards (Ind AS') specified under Section 133 of the Companies Act, 2013, as amended read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ratnam Dhaveji & Co
Chartered Accountants
Regd No 0066775

C V Ratnam Dhaveji



C V Ratnam Dhaveji
Partner, M.No 203479
UDIN: 19203479AAAAAF5861
Hyderabad
14.08.2019

MEDINOVA DIAGNOSTIC SERVICES LIMITED

CIN: L85110TG1993PLC015481

Regd. Office : 7-1-58/A/ FF8 , Flat No. 8, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

UNAUDITED - CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2019

(Rs. in Lakhs)

Sl. No.	Particulars	Quarter Ended			Year Ended
		30.06.2019 (Unaudited)	31.03.2019 (Unaudited)	30.06.2018 (Unaudited)	31.03.2019 (Audited)
1	Income:				
	(a) Revenue from operations	198.81	222.06	226.97	897.26
	(b) Other Income	0.11	7.94	1.67	9.98
	Total Income	198.92	230.00	228.64	907.24
2	Expenses				
	(a) Cost of Material Consumed	27.85	29.20	37.40	132.90
	(b) Employees benefit Expense	45.78	53.37	56.45	219.94
	(c) Finance Costs	16.32	16.17	12.39	65.88
	(d) Depreciation & Amortisation Expenses	23.54	32.30	31.77	128.52
	(e) Other Expenses	90.92	103.36	107.55	412.38
	Total Expenses	204.41	234.40	245.56	959.62
3	Profit / (Loss) before Exceptional and Extraordinary items and Tax (1-2)	(5.49)	(4.40)	(16.92)	(52.38)
4	Exceptional Items	-	161.32	-	161.32
5	Profit / (Loss) before Extraordinary items and Tax (3+4)	(5.49)	156.92	(16.92)	108.94
6	Extraordinary Items	-	-	-	-
7	Profit / (Loss) before Tax (5-6)	(5.49)	156.92	(16.92)	108.94
8	Tax Expenses				
	(a) Current Tax	-	-	-	-
	(b) Deferred Tax (Credit) / Charge	-	(5.85)	-	(5.85)
	(c) Taxes of earlier years	-	32.50	-	32.50
9	Profit / (Loss) for the period (7-8)	(5.49)	130.27	(16.92)	82.29
10	Other Comprehensive Income	-	(1.57)	0.00	(1.57)
11	Total Comprehensive income for the period (9+10)	(5.49)	128.70	(16.92)	80.72
	Net Profit attributable to:				
	(a) Owners of the Company	(8.56)	126.21	(13.92)	81.23
	(b) Non Controlling Interest	3.07	4.06	(3.00)	1.06
	Other Comprehensive Income attributable to:				
	(a) Owners of the Company	-	(1.57)	-	(1.57)
	(b) Non Controlling Interest	-	-	-	-
	Total Comprehensive Income attributable to:				
	(a) Owners of the Company	(8.56)	124.64	(13.92)	79.66
	(b) Non Controlling Interest	3.07	4.06	(3.00)	1.06
12	Paid-up Equity Share capital (Face Value Rs 10/- per share)	995.68	995.68	995.68	995.68
13	Earnings per Equity Share				
	a) Basic (Rs.)	(0.09)	1.25	(0.14)	0.80
	b) Diluted (Rs.)	(0.09)	1.25	(0.14)	0.80

Notes to Consolidated Financial Results for the Quarter Ended 30th June, 2019

- The consolidated financial results of the company have been prepared in accordance with the Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act., 2013, read with the relevant rules issued thereunder.
- The above financial results were reviewed by the Audit Committee and have been considered and approved by the Board of Directors at its meeting held on 14th August, 2019. The statutory Auditors of the company have carried out limited review of these results and the results are being published in accordance with regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.
- As the company's business activity falls within a single primary business segment (viz Diagnostic Services) the disclosure requirements of Accounting Standard (AS-108) "Operating Segments" issued by the Institute of Chartered Accountants of India are not applicable.
- Figures for the previous periods have been regrouped /rearranged wherever necessary to conform with the current period.

for MEDINOVA DIAGNOSTIC SERVICES LTD.

SUNIL CHANDRA KONDAPALLY
MANAGING DIRECTOR
DIN 01409332



Place : Hyderabad

Date : 14.08.2019



Limited Review Report on Unaudited Consolidated Financial Results

To
The Board of Directors,
Medinova Diagnostic Services Limited,
Hyderabad

1. We have reviewed the accompanying statement of unaudited Consolidated financial results of Medinova Diagnostic Services Limited ("the Parent") and its subsidiary LLP (together referred to as the as the "Group") for the Quarter ended 30th June 2019, ("the Statements") being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulations), as modified by Circular. No. CIR/CFD/CMD1/44/2019 dated 29th March 2019 ('the Circular').
2. The preparation of "the Statement" in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting' principles generally accepted in India read with circular is the responsibility of the Company management and has been approved by the Board of Directors of the Company in their meeting held on 14th August 2019. Our responsibility is to express a conclusion on "the Statement" based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable

4. The Statement includes the results of the following entities:

S.No	Name of the Entity	Nature of Relation
1.	Medinova Diagnostics Services Limited	The Parent
2.	Medinova Millennium MRI Services LLP	The Subsidiary LLP

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements, prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 as amended with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ratnam Dhaveji & Co
Chartered Accountants
Regd No 0066775



C V Ratnam Dhaveji
C V Ratnam Dhaveji
Partner, M.No 203479
UDIN: 19203479AAAAAE6135
Hyderabad
14.08.2019